CER 001

Drug Profile

CER 001

Alternative Names: CER-001; Cerenis HDL; Recombinant Human Apolipoprotein A-I; Recombinant Human Apolipoprotein A-I/Phospholipids complex

Latest Information Update: 10 Feb 2017

Price : $50

At a glance

  • Originator Cerenis Therapeutics
  • Developer Academic Medical Center; Cerenis Therapeutics
  • Class Antihyperlipidaemics; Apolipoprotein therapeutics; Phospholipids; Recombinant proteins
  • Mechanism of Action Apolipoprotein A I stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hypoalphalipoproteinaemia
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Hypoalphalipoproteinaemia
  • Phase II Acute coronary syndromes; Atherosclerosis
  • Phase I Lipid metabolism disorders

Most Recent Events

  • 01 Dec 2016 Cerenis Therapeutics completes the CARAT trial in Acute Coronary Syndrome in USA, Australia, Hungary and Netherlands (NCT02484378)
  • 27 Aug 2016 Safety data from the clinical development programmes for CER 001 presented by Cerenis Therapeutics at the Annual Congress of the European Society of Cardiology (ACS-2016)
  • 01 Aug 2016 Cerenis Therapeutics completes enrolment in the phase II CARAT trial for Acute Coronary Syndrome in USA, Australia, Hungary and the Netherlands
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top